Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (49)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chan, A. T. C.
Right arrow Articles by Johnson, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, A. T. C.
Right arrow Articles by Johnson, P. J.
Related Collections
Right arrow 2002 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1007-1015, 2002
© 2002 European Society for Medical Oncology

Review Article

Nasopharyngeal carcinoma

A. T. C. Chan+, P. M. L. Teo and P. J. Johnson

Prince of Wales Hospital, Sir Y. K. Pao Cancer Center, Chinese University of Hong Kong, People’s Republic of China

Received 20 December 2001; revised and accepted 8 February 2002

Abstract

Nasopharyngeal carcinoma (NPC) is endemic in southern China where genetic abnormalities and Epstein–Barr virus (EBV) infection are critical in the pathogenesis of the disease. Circulating EBV-DNA has been shown to improve prognostication and monitoring of NPC patients. Radiotherapy is the mainstay treatment for early disease and concurrent cisplatin/radiotherapy has been demonstrated to prolong survival in locoregionally advanced disease. Ongoing studies of targeting agents and immunotherapeutic approaches may further improve treatment results.

Key words: Epstein–Barr virus, nasopharyngeal carcinoma, review, treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
J.-S. Wang, C.-Y. Chang, S.-E. Chow, Y.-W. Chen, and C.-M. Yang
Exercise modulates platelet-nasopharyngeal carcinoma cell aggregation and subsequent tissue factor and matrix metalloproteinase activities
J Appl Physiol, September 1, 2007; 103(3): 763 - 770.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. T.-C. Chang, S.-H. Chan, C.-Y. Lin, T.-Y. Lin, H.-M. Wang, C.-T. Liao, T.-H. Wang, L.-Y. Lee, and A.-J. Cheng
Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15
Mol. Cancer Ther., August 1, 2007; 6(8): 2271 - 2279.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
L.-M. Sun, C. I. Li, E.-Y. Huang, and T. L. Vaughan
Survival Differences by Race in Nasopharyngeal Carcinoma
Am. J. Epidemiol., February 1, 2007; 165(3): 271 - 278.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. N. Heller, J. Upshaw, B. Seyoum, H. Zebroski, and C. Munz
Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers
Blood, February 1, 2007; 109(3): 1138 - 1146.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-N. Qian, B. Berghuis, G. Tsarfaty, M. Bruch, E. J. Kort, J. Ditlev, I. Tsarfaty, E. Hudson, D. G. Jackson, D. Petillo, et al.
Preparing the "Soil": The Primary Tumor Induces Vasculature Reorganization in the Sentinel Lymph Node before the Arrival of Metastatic Cancer Cells
Cancer Res., November 1, 2006; 66(21): 10365 - 10376.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
L. M. Richey, A. F. Olshan, J. George, C. G. Shores, A. M. Zanation, T. Cannon, and M. C. Weissler
Incidence and survival rates for young blacks with nasopharyngeal carcinoma in the United States.
Arch Otolaryngol Head Neck Surg, October 1, 2006; 132(10): 1035 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. K. Tai, M. Lin, F. Chang, G. Chen, F. Hsiao, N. Sutkowski, and B. T. Huber
Murine Vbeta3+ and Vbeta7+ T Cell Subsets Are Specific Targets for the HERV-K18 Env Superantigen.
J. Immunol., September 1, 2006; 177(5): 3178 - 3184.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Comoli, P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, M. Labirio, R. Schiavo, S. Secondino, C. Frasson, C. Perotti, et al.
Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes
J. Clin. Oncol., December 10, 2005; 23(35): 8942 - 8949.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. C. Straathof, A. M. Leen, E. L. Buza, G. Taylor, M. H. Huls, H. E. Heslop, C. M. Rooney, and C. M. Bollard
Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma
J. Immunol., September 15, 2005; 175(6): 4137 - 4147.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. C. M. Straathof, C. M. Bollard, U. Popat, M. H. Huls, T. Lopez, M. C. Morriss, M. V. Gresik, A. P. Gee, H. V. Russell, M. K. Brenner, et al.
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes
Blood, March 1, 2005; 105(5): 1898 - 1904.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.A. Langendijk, Ch.R. Leemans, J. Buter, J. Berkhof, and B.J. Slotman
The Additional Value of Chemotherapy to Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Meta-Analysis of the Published Literature
J. Clin. Oncol., November 15, 2004; 22(22): 4604 - 4612.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Xiong, Z. Y. Zeng, J. H. Xia, K. Xia, S. R. Shen, X. L. Li, D. X. Hu, C. Tan, J. J. Xiang, J. Zhou, et al.
A Susceptibility Locus at Chromosome 3p21 Linked to Familial Nasopharyngeal Carcinoma
Cancer Res., March 15, 2004; 64(6): 1972 - 1974.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Kerr
A little citadel of light in a malignant sea of darkness
Ann. Onc., January 1, 2004; 15(1): 1 - 2.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P. Comoli, R. De Palma, S. Siena, A. Nocera, S. Basso, F. Del Galdo, R. Schiavo, O. Carminati, A. Tagliamacco, G. F. Abbate, et al.
Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma
Ann. Onc., January 1, 2004; 15(1): 113 - 117.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Cackett, J. Stebbing, and B. Dhillon
Complications of Therapy and a Diagnostic Dilemma Case: CASE 1. RADIATION MACULOPATHY FOLLOWING TREATMENT OF NASOPHARYNGEAL CARCINOMA
J. Clin. Oncol., December 15, 2003; 21(24): 4650 - 4651.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.